|
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Colorectal Neoplasms
|
0.100 |
GeneticVariation
|
group |
GWASCAT |
Genome-wide association study and meta-analysis in Northern European populations replicate multiple colorectal cancer risk loci.
|
28960316 |
2018 |
|
Colorectal Neoplasms
|
0.100 |
GeneticVariation
|
group |
GWASCAT |
Association analyses identify 31 new risk loci for colorectal cancer susceptibility.
|
31089142 |
2019 |
|
Colorectal Neoplasms
|
0.100 |
GeneticVariation
|
group |
GWASCAT |
Discovery of common and rare genetic risk variants for colorectal cancer.
|
30510241 |
2019 |
|
Colorectal Neoplasms
|
0.100 |
GeneticVariation
|
group |
GWASCAT |
Novel Common Genetic Susceptibility Loci for Colorectal Cancer.
|
29917119 |
2019 |
|
Deglutition Disorders
|
0.100 |
Biomarker
|
group |
HPO |
|
|
|
|
Inflammatory Bowel Diseases
|
0.100 |
GeneticVariation
|
group |
GWASCAT |
Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease.
|
23128233 |
2012 |
|
Inflammatory Bowel Diseases
|
0.100 |
GeneticVariation
|
group |
GWASCAT |
Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease.
|
28067908 |
2017 |
|
Inflammatory Bowel Diseases
|
0.100 |
GeneticVariation
|
group |
GWASDB |
Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease.
|
23128233 |
2012 |
|
Speech Disorders
|
0.100 |
Biomarker
|
group |
HPO |
|
|
|
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Therefore, our findings suggest that MR-1 functions as a tumor promoter in MCF7 cells by activating the MEK/ERK signaling.
|
25066297 |
2014 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
These findings provide compelling evidence that MR-1 might be a diagnostic marker and therapeutic target for solid tumours, myelogenous leukaemia and PNKD.
|
29103325 |
2018 |
|
Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
The correlation was analyzed between the expression of MR-1 and other tumor characteristics which may influence the prognosis of gastric cancer patients.
|
23082061 |
2012 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Silencing MR-1 inhibits cancer cell proliferation and metastasis.
|
29103325 |
2018 |
|
Malignant Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Myofibrillogenesis regulator-1 (MR-1) expression was detected in different malignancies and is associated with poor prognosis.
|
23696030 |
2013 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
Silencing MR-1 inhibits cancer cell proliferation and metastasis.
|
29103325 |
2018 |
|
Primary malignant neoplasm
|
0.020 |
AlteredExpression
|
group |
BEFREE |
In this study, MR-1 protein expression was determined by immunohistochemistry in specimens of primary cancer and the adjacent noncancerous tissues from gastric cancer patients.
|
23082061 |
2012 |
|
Liver neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
MR-1S is overexpressed in haematologic and solid malignancies, such as hepatoma, breast cancer and chronic myelogenous leukaemia.
|
29103325 |
2018 |
|
Movement Disorders
|
0.010 |
GeneticVariation
|
group |
BEFREE |
This study highlights the frequency, novel mutations and clinical and molecular spectrum of PRRT2, SLC2A1 and PNKD mutations as well as the phenotype-genotype overlap among these paroxysmal movement disorders.
|
26598494 |
2015 |
|
Parkinsonian Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
Combined dystonias (with parkinsonism or myoclonus) are further subdivided into persistent (TAF1 [DYT3], GCHI [DYT5], SGCE [DYT11], ATP1A3 [DYT12]), PRKRA (DYT16), and paroxysmal (MR-1 [DYT8], PRRT2 [DYT10], SLC2A1 [DYT18].
|
23893446 |
2013 |
|
Dystonia Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
Inherited dystonia designated by DYT locus symbols can be separated into three broad phenotypic categories: primary torsion dystonia (PTD), where dystonia is the only clinical sign (except for tremor) (DYT1, 2, 4, 6, 7, 13, 17, and 21); dystonia plus loci, where other phenotypes in addition to dystonia, including parkinsonism or myoclonus, are present (DYT3, 5/14, 11, 12, 15, and 16); and paroxysmal forms of dystonia/dyskinesia (DYT8, 9, 10, 18, 19, and 20).
|
22266882 |
2011 |
|
Other dystonia
|
0.200 |
Biomarker
|
phenotype |
MGD |
|
|
|
|
Dystonia, Paroxysmal
|
0.110 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Dystonia, Paroxysmal
|
0.110 |
CausalMutation
|
phenotype |
CLINVAR |
|
|
|
|
Dystonia, Paroxysmal
|
0.110 |
GeneticVariation
|
phenotype |
BEFREE |
In addition, six other dystonia gene loci have been mapped to chromosomal regions, including a locus for a mixed dystonia phenotype (DYT6), one form of focal dystonia (DYT7), two types of paroxysmal dystonia (DYT8, DYT9), X-linked dystonia-parkinsonism (DYT3), and rapid-onset dystonia parkinsonism (DYT12).
|
12194383 |
1999 |